| Literature DB >> 25736003 |
Peter L Greenberg1, Richard M Stone1, Rafael Bejar1, John M Bennett1, Clara D Bloomfield1, Uma Borate1, Carlos M De Castro1, H Joachim Deeg1, Amy E DeZern1, Amir T Fathi1, Olga Frankfurt1, Karin Gaensler1, Guillermo Garcia-Manero1, Elizabeth A Griffiths1, David Head1, Virginia Klimek1, Rami Komrokji1, Lisa A Kujawski1, Lori J Maness1, Margaret R O'Donnell1, Daniel A Pollyea1, Bart Scott1, Paul J Shami1, Brady L Stein1, Peter Westervelt1, Benton Wheeler1, Dorothy A Shead1, Courtney Smith1.
Abstract
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.Entities:
Mesh：
Year: 2015 PMID： 25736003 PMCID： PMC4696005 DOI： 10.6004/jnccn.2015.0038
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908